Lumisight Injection, Powder, Lyophilized, For Solution
Product Images NDC 82292-040

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lumisight (NDC 82292-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lumicell, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Spl 1)

Image Description (Spl 1)
Chemical structure of Pegulicianine, the active ingredient in LUMISIGHT injection, powder, lyophilized, for solution. The diagram shows the detailed molecular structure with various functional groups and stereochemistry as part of the complex peptide-like molecule.*
FDA Label Image

Image Description (Spl 2)

Image Description (Spl 2)
Label for LUMISIGHT (pegulicianine for injection) 39 mg single-dose vial. Instructions indicate use after reconstitution with 0.45% sodium chloride injection, USP. Storage guidance states to keep at 20-25°C for up to 4 hours or refrigerated at 2-8°C for up to 24 hours, with protection from light. Label includes NDC 82292-040-01 and manufacturer Lumicell, Inc.*
FDA Label Image

Image Description (Spl 3)

Image Description (Spl 3)
Packaging label for LUMISIGHT (pegulicianine) injection, 39 mg per vial, a lyophilized powder for intravenous use. The carton design features blue and white colors with the Lumicell, Inc. logo. The label indicates storage and reconstitution instructions, recommended dose guidance, and notes that the product contains 10 single-dose vials. A barcode and lot/expiration date area are also visible.*
FDA Label Image

Table1 (Table 1)

Table1 (Table 1)
A data table titled 'Image-level performance of LUMISIGHT for detection of residual breast cancer in the lumpectomy cavity after completion of standard of care lumpectomy.' It presents LUMISIGHT imaging results compared to a reference standard, including counts of positive and negative detections, totals, and diagnostic performance metrics such as sensitivity (49.1%) and specificity (86.5%) with 95% confidence intervals.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.